BioPharm International-10-01-2004

BioPharm International

Editorial—Where's the Money?

October 01, 2004

Columns and Departments

17

10

Let's be frank. Love doesn't make the world go round —money does, especially if you're developing a promising technology but you're facing ten or fifteen more years of bench time and clinical trials before you can unveil a marketable product.

StreetTalk: Corporate Wellness Programs

October 01, 2004

Columns and Departments

17

10

We've gone beyond the days when corporate America's idea of a healthy outing was a company softball game complete with beer and hot dogs.

Regulatory Beat: Pharmacogenomics Discoveries Shape Biotech R&D

October 01, 2004

Columns and Departments

17

10

Even if FDA does not require pharma companies to co-market a diagnostic test, insurers and health plans may pressure industry to do so, according to Robert Temple of CDER.

Biotech Industry Finds Fertile Ground in the Netherlands

October 01, 2004

International BioMarket

17

10

Though still relatively modest by international standards, the Netherlands' biotechnology industry has made impressive gains in recent years and now provides investors with a compelling alternative to more established European "heavyweights" such as Scandinavia, Switzerland, and the United Kingdom.

Supply Chain Cycle Time Reduction

October 01, 2004

Quality

17

10

Wyeth BioPharma has identified cycle-time reduction as critical to customer responsiveness and the success of commercial and pipeline products. In formulating a plan of attack, the company focused on two aspects of cycle time: the global planning process and disposition cycle times.

Final Word: Riding on the Coattails of US Patients

October 01, 2004

Columns and Departments

17

10

In general, people in other countries pay less for brand-name prescription drugs than people in the US. As a result, some Americans travel to Canada or Mexico to get their prescriptions, and an increasing number are using the Internet to buy drugs from other countries.